Obesity in pediatric oncology

Area of Science:

• Pediatric Oncology
• Obesity Epidemiology
• Cancer Pharmacology

Background:

• The global obesity pandemic is a growing concern, with increasing prevalence in all pediatric age groups in the US.
• The influence of obesity on childhood cancer outcomes remains largely unknown.
• Obesity is linked to various health issues, including increased mortality in certain adult cancer populations.

Purpose of the Study:

• To summarize current knowledge on obesity's impact on childhood cancer, drawing from a Children's Oncology Group symposium.
• To highlight key findings regarding obesity, chemotherapy, and outcomes in pediatric cancer patients.
• To identify areas for future research and intervention.

Main Methods:

• Review of symposium discussions covering obesity epidemiology, chemotherapy pharmacology, and cancer outcomes in obese individuals (pediatric and adult).
• Analysis of body mass index (BMI) as a measure of obesity.
• Synthesis of data on treatment-related mortality, toxicity, relapse, and survival rates in obese pediatric cancer patients.

Main Results:

• Obesity prevalence is rising rapidly in US children, particularly among minority adolescents.
• Chemotherapy pharmacokinetics (half-life, distribution, clearance) vary in obese patients, suggesting potential underdosing or altered toxicity.
• Obese pediatric patients with acute myeloid leukemia (AML) exhibit higher treatment-related mortality, similar toxicity and relapse rates, but inferior survival.
• Female survivors of childhood leukemia treated with cranial irradiation have a higher incidence of obesity.

Conclusions:

• Obesity poses significant challenges in pediatric cancer care, impacting treatment outcomes and survival.
• There is a need for studies analyzing chemotherapy pharmacology by BMI and investigating obesity's broader impact on pediatric cancer.
• Preventative measures for obesity and promotion of healthy lifestyles are essential for childhood cancer patients and survivors.